Literature DB >> 3743624

Influence of dose and route of administration on disposition of metronidazole and its major metabolites.

S Loft, M Døssing, H E Poulsen, J Sonne, K L Olesen, K Simonsen, P B Andreasen.   

Abstract

The influence of dose and route of administration on the kinetics of metronidazole and its major metabolites has been investigated in 8 healthy volunteers given 0.5 and 2.0 g i.v. and p.o. Metronidazole elimination kinetics from plasma could be described by an open two-compartment model. The systemic oral bioavailability of both doses was approximately 1. The total systemic clearance of the intravenous 2.0 g dose was 9% lower than that of the 0.5 g dose (p less than 0.05). There were no significant dose-related differences in volume or rate of distribution. The elimination half-life was similar after the four treatments with metronidazole. The major elimination pathways, renal excretion and hepatic oxidation and glucuronidation, accounted for more than 2/3 of the total systemic clearance. Clearance both by hepatic oxidative metabolism and renal excretion was significantly lower after 2.0 than after 0.5 g i.v., whereas there was no significant difference after the oral doses. The results indicate that a high therapeutic dose of metronidazole may be eliminated at a reduced rate, but this is probably not of clinical importance. No single saturable elimination pathway was identified.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3743624     DOI: 10.1007/bf00607962

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Pharmacokinetics of tinidazole and metronidazole in women after single large oral doses.

Authors:  B A Wood; A M Monro
Journal:  Br J Vener Dis       Date:  1975-02

Review 2.  Drug metabolite kinetics.

Authors:  J B Houston
Journal:  Pharmacol Ther       Date:  1981       Impact factor: 12.310

Review 3.  Drug therapy: metronidazole.

Authors:  J Koch-Weser; P Goldman
Journal:  N Engl J Med       Date:  1980-11-20       Impact factor: 91.245

4.  High-dose metronidazole: pharmacokinetics and bioavailability using an iv preparation and application of its use as a radiosensitizer.

Authors:  H R Rabin; R C Urtasun; J Partington; D Koziol; M Sharon; K Walker
Journal:  Cancer Treat Rep       Date:  1980 Oct-Nov

5.  Comparison of the pharmacokinetics of metronidazole in healthy female volunteers following either a single oral or intravenous dose.

Authors:  G W Houghton; P S Thorne; J Smith; R Templeton; J Collier
Journal:  Br J Clin Pharmacol       Date:  1979-10       Impact factor: 4.335

6.  The pharmacokinetics of oral and intravenous metronidazole in man.

Authors:  G W Houghton; J Smith; P S Thorne; R Templeton
Journal:  J Antimicrob Chemother       Date:  1979-09       Impact factor: 5.790

7.  Pharmacokinetics and bioavailability of metronidazole after tablets, suppositories and intravenous administration.

Authors:  T Bergan; O Leinebo; T Blom-Hagen; B Salvesen
Journal:  Scand J Gastroenterol Suppl       Date:  1984

8.  Comparative pharmacokinetic studies of ornidazole and metronidazole in man.

Authors:  D E Schwartz; F Jeunet
Journal:  Chemotherapy       Date:  1976       Impact factor: 2.544

9.  The pharmacokinetics of one single preoperative dose of metronidazole or tinidazole.

Authors:  J H Solhaug; T Bergan; O Leinebø; A R Rosseland; L Spada; F Vaagenes
Journal:  Scand J Gastroenterol Suppl       Date:  1984

10.  Human pharmacokinetics and toxicity of high-dose metronidazole administered orally and intravenously.

Authors:  R C Urtasun; H R Rabin; J Partington
Journal:  Surgery       Date:  1983-01       Impact factor: 3.982

View more
  15 in total

1.  The effect of dietary energy and protein deficiency on drug metabolism.

Authors:  O Hamberg; L Ovesen; A Dorfeldt; S Loft; J Sonne
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Disposition of intravenous metronidazole in Asian surgical patients.

Authors:  T Y Ti; H S Lee; Y M Khoo
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

3.  Antipyrine and metronidazole metabolism during occupational exposure to gasoline.

Authors:  M Døssing; S Loft; J Sonne; E Schroeder
Journal:  Int Arch Occup Environ Health       Date:  1988       Impact factor: 3.015

4.  Use of metabolite AUC data in bioavailability studies to discriminate between absorption and first-pass extraction.

Authors:  M Weiss
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

5.  Inhibition and induction of metronidazole and antipyrine metabolism.

Authors:  S Loft; J Sonne; H E Poulsen; K T Petersen; B G Jørgensen; M Døssing
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 6.  Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.

Authors:  K C Lamp; C D Freeman; N E Klutman; M K Lacy
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

7.  Evaluating metronidazole as a novel, safe CYP2A6 phenotyping probe in healthy adults.

Authors:  Stephani L Stancil; Robin E Pearce; Rachel F Tyndale; Gregory L Kearns; Carrie A Vyhlidal; J Steven Leeder; Susan Abdel-Rahman
Journal:  Br J Clin Pharmacol       Date:  2019-03-12       Impact factor: 4.335

Review 8.  Metronidazole. A therapeutic review and update.

Authors:  C D Freeman; N E Klutman; K C Lamp
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

Review 9.  Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives.

Authors:  A H Lau; N P Lam; S C Piscitelli; L Wilkes; L H Danziger
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

10.  In vitro activities of metronidazole and its hydroxy metabolite against Bacteroides spp.

Authors:  S L Pendland; S C Piscitelli; P C Schreckenberger; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.